Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2014
Price : $35 *
At a glance
- Drugs NN 9926 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 19 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Feb 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.